Nuvalent (NUVL) Amortizatization of Intangibles (2021 - 2026)
Nuvalent (NUVL) reported Amortizatization of Intangibles of $1.8 million for Q1 2026, down 57.27% on a YoY basis from $4.3 million in Q1 2025, and down 90.98% quarter-over-quarter from $20.3 million in Q4 2025.
Nuvalent (NUVL) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Nuvalent has reported Amortizatization of Intangibles for 6 years, with the latest figure at $1.8 million in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 57.27% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $8.7 million (down 61.25% YoY), and the FY2025 full-year result was $11.1 million, down 24.28% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $1.8 million, down from $20.3 million in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $24.4 million in Q4 2024, with the low at -$11.3 million in Q2 2025.
- Historically, Amortizatization of Intangibles has averaged $2.2 million across 5 years, with a median of -$833000.0 in 2022.
- The largest YoY upside for Amortizatization of Intangibles was 2275.99% in 2023 against a maximum downside of 87566.67% in 2023.
- Nuvalent's Amortizatization of Intangibles stood at -$833000.0 in 2022, then surged by 2275.99% to $18.1 million in 2023, then surged by 34.64% to $24.4 million in 2024, then retreated by 16.89% to $20.3 million in 2025, then plunged by 90.98% to $1.8 million in 2026.
- The last three Amortizatization of Intangibles figures came in at $1.8 million (Q1 2026), $20.3 million (Q4 2025), and -$2.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | 1.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.83 Mn |
| Mar 31, 2026 | 1.83 Mn |
| Dec 31, 2025 | 20.28 Mn |
| Dec 31, 2025 | 20.28 Mn |
| Sep 30, 2025 | -2.19 Mn |
| Sep 30, 2025 | -2.19 Mn |
| Jun 30, 2025 | -11.27 Mn |
| Jun 30, 2025 | -11.27 Mn |
| Mar 31, 2025 | 4.28 Mn |
| Mar 31, 2025 | 4.28 Mn |
| Dec 31, 2024 | 24.41 Mn |
| Dec 31, 2024 | 24.41 Mn |
| Sep 30, 2024 | -2.92 Mn |
| Sep 30, 2024 | -2.92 Mn |
| Jun 30, 2024 | -3.43 Mn |
| Jun 30, 2024 | -3.43 Mn |
| Mar 31, 2024 | -3.38 Mn |
| Mar 31, 2024 | -3.38 Mn |
| Dec 31, 2023 | 18.13 Mn |
| Dec 31, 2023 | 18.13 Mn |